Jabil Delivers Solid Fourth Quarter & Fiscal Year 2015 Results

Company Exceeds Expectations and Raises Outlook for Fiscal 2016

ST. PETERSBURG, Fla.-- Today Jabil Circuit, Inc. (JBL), announced preliminary, unaudited financial results for its fourth quarter and full fiscal year, ended August 31, 2015. The company reported fourth quarter net revenue of $4.7 billion and fiscal year net revenue of $17.9 billion.

“I am extremely pleased with our fiscal 2015 results and in particular the financial strength demonstrated as we exited the year. We exceeded nearly every financial target provided at the outset of the year, culminating with core earnings per share of $2.07 and free cash flow of approximately $300 million,” said Mark T. Mondello, Chief Executive Officer. “Our strong cash generation provided us the financial flexibility to complete a number of strategic acquisitions, aggressively re-invest in the business and return approximately $150 million to shareholders via dividend and share repurchases,” he added.

Metanor Intersects 10.1 g/t Au Over 26.2 Meters Near Surface

VAL-D'OR, QUEBEC--(Sep 22, 2015) - Metanor Resources Inc. ("Metanor") (TSX VENTURE:MTO) is pleased to provide this update on its exploration drilling program, from the surface, in the area surrounding the Bachelor Mine. A surface drill located 925 meters south of the Bachelor Mine has intersected 10.1 g/t over 26.2 meters of drill cores assayed. The drilling continues in the same hole since there are more potential targets at depth. This result is part of a drill campaign that is a following up from holes drilled in 2013 and a geophysical survey completed in the fall 2014 in the region surrounding Bachelor Mine. See the press release published March 12, 2015 for more details.

Initially, hole MO-15-08 was drilled in August. See the attached plan for the collar location. Following the results obtained from this first hole, a geophysical survey using a hole to hole - Induced polarization (H2H IP) method was conducted in the first hole, and indicated a large anomaly in the area. A second surface drill rig was brought in to drill hole MO-15-14. The location of the second hole targeted the large anomaly.

Aerie Pharmaceuticals Reports Positive Rhopressa™ Phase 3 Efficacy Results

Rhopressa^™ Achieves Primary Clinical Endpoint in Rocket 2 Study

Conference Call and Webcast Today, September 16, at 5:00 p.m. ET

IRVINE, Calif.--- Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class glaucoma therapies, today reported the successful results of its second Phase 3 trial for Rhopressa^™, a novel once-daily, triple-action eye drop being tested for its ability to lower intraocular pressure (IOP) in patients with glaucoma or ocular hypertension. The trial achieved its primary efficacy endpoint demonstrating non-inferiority of Rhopressa^™ compared to timolol, the most widely used comparator. Management will host a conference call and provide accompanying slides to discuss these results at 5:00 p.m. ET today.

Nanosphere Receives FDA Clearance for First-of-Its-Kind Flexible Respiratory Pathogens Test

NORTHBROOK, Ill., Sept. 8, 2015  -- Nanosphere, Inc. (NSPH), a company enhancing the practice of medicine through targeted molecular diagnostics, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its Verigene(R) Respiratory Pathogens Flex Nucleic Acid Test (RP Flex) on the automated sample-to-result Verigene System.

The first test of its kind, RP Flex features Nanosphere's novel Flex(TM) software, which allows the 16 viral and bacterial targets identified by RP Flex to be reported as a full multiplex panel or in various user-defined subsets. Labs pay for only the targets ordered for each patient sample. The flexible panel concept addresses the varied respiratory testing needs of labs and clinicians with a single comprehensive, yet cost-effective solution.